University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Benefits of β blockers in chronic obstructive pulmonary disease and heart failure

Creagh-Brown, Ben (2014) Benefits of β blockers in chronic obstructive pulmonary disease and heart failure BMJ, 348, g3316.

Full text not available from this repository.

Abstract

Williams and Oakeshott caution against the use of the β blocker bisoprolol for chronic heart failure in patients with severe asthma or chronic obstructive pulmonary disease (COPD).1 This recommendation is somewhat contentious. Patients with COPD often have cardiac comorbidities, including chronic heart failure (~20% of patients2), and in one large study of patients with COPD, 27% of deaths were attributable to cardiac causes.3 Selective β blockers such as bisoprolol have been shown to be safe in COPD.4 5 Moreover, in addition to the beneficial effects on outcomes relating to heart failure, there is mounting evidence that β blockade may also improve outcomes from COPD.6

Item Type: Article
Divisions : Faculty of Health and Medical Sciences > School of Biosciences and Medicine
Authors :
NameEmailORCID
Creagh-Brown, Benb.creagh-brown@surrey.ac.uk
Date : 19 May 2014
DOI : 10.1136/bmj.g3316
Depositing User : Clive Harris
Date Deposited : 19 Mar 2019 09:54
Last Modified : 19 Mar 2019 09:54
URI: http://epubs.surrey.ac.uk/id/eprint/850766

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800